Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-552 Single Dose in Sjogren's Xerostomia
NCT01369589Phase 2Completed
- Sponsor
- Parion Sciences
- Start
- Nov 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 552-02 in xerostomia and Sjogren's syndrome (2 arms), sponsored by Parion Sciences. Primary endpoint: Salivary volume. Started Nov 2010; status: completed.
02
Drugs
552-02
03
Conditions
xerostomiaSjogren's syndrome
Beyond the preview
Go deeper on NCT01369589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369589.